1 / 36

PrEP : HIV Pre-exposure Prophylaxis

PrEP : HIV Pre-exposure Prophylaxis. Katherine Marx, MS, MPH, FNP-BC. June 2014. Disclosure. I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose. Objectives. Know current US recommendations for PrEP Identify candidates for PrEP

johana
Download Presentation

PrEP : HIV Pre-exposure Prophylaxis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014

  2. Disclosure I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose.

  3. Objectives • Know current US recommendations for PrEP • Identify candidates for PrEP • Learn about resources for providing PrEP

  4. Combination HIV Prevention • Biomedical Interventions • Behavioral Interventions • Structural Interventions

  5. Biomedical Interventions • PrEP • Post-exposure prophylaxis • Treatment as prevention • Diagnosis and treatment of sexually transmitted infections • Prevention of mother-to-child transmission of HIV • Contraception to prevent unplanned pregnancy among women with HIV • Voluntary male circumcision • Blood safety • Injection safety • Microbicides

  6. PrEP: Pre-exposure Prophylaxis • How does it work? • Uninfected person takes antiretrovirals • May prevent replication of virus & infection • Daily adherence to TDF/FTC

  7. NRTI’s and NNRTI’s work here http://www.aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle

  8. PrEP Timeline August 2012 TDF2 Partners PrEP June 2013 Bangkok TDF Study November 2010 iPrEx March 2013 VOICE July 2012 FEM-PrEP June 2013 CDC Interim Guidance: PrEP for IDU July 2012 FDA Approval TDF/FTC PrEP January 2011 CDC Interim Guidance: PrEP for MSM January 2014 NYS AIDS Institute Guidance for PrEP August 2012 CDC Interim Guidance: PrEP for heterosexuals May 2014 US Public Health Service Clinical Practice Guideline for PrEP

  9. PrEP Studies: HIV transmission risk lowest when participants took PrEP consistently Adapted from summary of research at http://www.cdc.gov/hiv/prevention/research/prep/

  10. PrEP Utilization Female Male Rawlings K, Mera R, Pechonkina A, et al. Status of Truvada for HIV pre-exposure prophylaxis (PrEP) in the United States: an early drug utilization analysis. 53rd ICAAC. September 10-13, 2013. Denver. Abstract H-663a.

  11. PrEP: Candidates Substantial risk of acquiring HIV infection • Men who have sex with men (MSM) • HIV-positive sexual partner • Recent bacterial STI • High number of sex partners • History of inconsistent/no condom use • Commercial sex work http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  12. PrEP: Candidates Substantial risk of acquiring HIV infection • Transgender individuals • Engaging in high-risk sexual behaviors www.hivguidelines.org

  13. Risk Behavior Assessment for MSM In the past 6 months: • Have you had sex with men, women, or both? • (if men or both sexes) How many men have you had sex with? • How many times did you have receptive anal sex (you were the bottom) with a man who was not wearing a condom? • How many of your male sex partners were HIV-positive? • (if any positive) With these HIV-positive male partners, how many times did you have insertive anal sex (you were the top) without you wearing the condom? • Have you used methamphetamines (such as crystal or speed)? http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  14. PrEP: Candidates Substantial risk of acquiring HIV infection • Heterosexual women and men • HIV-positive sexual partner • Recent bacterial STI • High number of sex partners • History of inconsistent/no condom use • Commercial sex work • High-prevalence area or network http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  15. PrEP: Candidates Substantial risk of acquiring HIV infection • Injection drug users (IDU) • HIV-positive injecting partner • Sharing injection equipment • Recent drug treatment (but currently injecting) http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  16. PrEP vs. nPEP Case #1: 24 year old white MSM who presents 4 hours after unprotected receptive anal sex, for the first time, with his HIV-infected partner.

  17. nPEP Non-occupational Post-exposure Prophylaxis • High risk exposure • As soon as possible • 28 day course • Tenofovir/emtricitabine + raltegravir www.hivguidelines.org

  18. PrEP vs. nPEP Case #2: 24 year old MSM on nPEP, day 27/28. Struggles with consistent condom use and regularly has unprotected receptive anal intercourse with his HIV-infected partner.

  19. PrEP: Clinical Eligibility • Documented negative HIV test • No signs/symptoms of acute HIV infection • Normal renal function • No contraindicated medications • Documented hepatitis B infection & vaccination status http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  20. PrEP: HIV Testing • Are signs/symptoms of acute HIV present now or in prior 4 weeks? • Option 1: retest antibody in one month • Option 2: HIV antibody/antigen assay • Option 3: HIV-1 viral load http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  21. Acute HIV Infection Symptoms • Fever • Fatigue • Myalgia • Skin rash • Headache • Pharyngitis • Cervical Lymphadenopathy • Arthralgia • Night sweats • Diarrhea Daar ES, Pilcher CD, Hecht FM. CurrOpin HIV AIDS. 2008;3(1):10-15.

  22. PrEP: Considerations • Age • Reproductive plan • Osteopenia/osteoporosis www.hivguidelines.org

  23. PrEP: Risk Reduction Case #3: 32 year old black female seeks pregnancy. She is not infected with HIV. Her partner is HIV-infected and not currently on antiretroviral treatment.

  24. Providing PrEP Every visit: Assess adherence Risk reduction counseling Provide condoms Before starting PrEP: • Clinical eligibility • Educate • Side effects • Limitations • Daily adherence • Symptoms of seroconversion • Monitoring schedule • Safety • Criteria for discontinuation • Partner information • Social history: housing, substance use, mental health, domestic violence www.hivguidelines.org

  25. Providing PrEP Every visit: Assess adherence Risk reduction counseling Provide condoms After confirmation of clinical eligibility: • Prescribe no more than 90-day supply of PrEP • Truvada 1 tablet PO daily (tenofovir 300mg + emtricitabine 200mg) • Insurance prior approval • Truvada for PrEP Medication Assistance Program http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  26. Providing PrEP Every visit: Assess adherence Risk reduction counseling Provide condoms 3-month visit: • HIV test • Assess for acute infection • Check for side effects • Pregnancy testing • Prescribe 90-day supply of medication http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  27. Providing PrEP Every visit: Assess adherence Risk reduction counseling Provide condoms 6-month • HIV test • STI test • Pregnancy test • Renal function • 90 day prescription 9-month • HIV test • Pregnancy test • 90 day prescription 12-month • HIV test • STI tests • Pregnancy test • Renal function • 90 day prescription • Assess the need to continue PrEP http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  28. Support Adherence Develop trust, avoid judgment • Plan • Monitor • Educate • Identify barriers • Assess for side effects http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  29. Discontinuing PrEP • Positive HIV result • Acute HIV signs or symptoms • Non-adherence • Renal disease • Changed life situation: lower HIV risk http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf

  30. PrEP: Research • PrEP in the real world • Intermittent dosing • New medications • New formulations

  31. PrEP Summary • Effective • FDA approved • Well-tolerated However, • Short-term data only • Daily adherence required • Side effects • Drug resistance in acute infection • Could lead to fewer condoms being used • Cost • Logistics

  32. PrEP Resources • CDC: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf • NYSDOH AI: http://www.hivguidelines.org/ • PrEP Watch/ AVAC: http://www.prepwatch.org/

  33. Additional Resources NY/NJ AETC PrEP Webinars • http://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14060902&securitycode=KXbFYh • http://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14052303&securitycode=01r27E • http://nynjaetc.virtualforum.com/pif.asp?Prog_ID=14050908&securitycode=o9k2C2

  34. Katherine Marx, MS, MPH, FNP-BC

More Related